Suppr超能文献

基于伴侣介导的自噬靶向嵌合纳米平台的信号转导和转录激活因子 3 的靶向降解

Targeted Degradation of Signal Transduction and Activator of Transcription 3 by Chaperone-Mediated Autophagy Targeting Chimeric Nanoplatform.

机构信息

CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.

Henan Institutes of Advanced Technology, Zhengzhou University, Zhengzhou 450052, China.

出版信息

ACS Nano. 2024 Jan 16;18(2):1599-1610. doi: 10.1021/acsnano.3c09536. Epub 2023 Dec 29.

Abstract

Chaperone-mediated autophagy (CMA) is a lysosomal-dependent proteolysis pathway for the degradation of cytosolic proteins. However, exploiting CMA-mediated proteolysis to degrade proteins of interest in cancer therapy has not been widely applied. In this study, we develop a CMA-targeting chimera (CMATAC) to efficiently and specifically degrade signal transduction and activator of transcription 3 (STAT3) in tumor cells. CMATAC consists of STAT3 and heat shock cognate 70 kDa protein (HSC70) targeting peptides connected by a linker. To efficiently deliver CMATACs into tumor cells, lipid nanoparticles (LNPs) are used to encapsulate CMATACs (nCMATACs) and decorated with an insulin-like growth factor 2 receptor (IGF2R) targeting peptide (InCMATACs) to achieve tumor targeting and precise delivery. The CMA pathway is activated in tumor cells by a fasting-mimicking diet (FMD). Furthermore, FMD treatment strongly enhances the cellular uptake and tumor accumulation of InCMATACs by upregulating the IGF2R expression. As a result, InCMATACs efficiently degrade STAT3 protein in both A549 and HCC827 tumor cells and inhibit tumor growths in vivo. This study demonstrates that InCMATACs can be used for selective proteolysis in cancer therapy.

摘要

伴侣蛋白介导的自噬(CMA)是一种溶酶体依赖性的蛋白降解途径,用于降解细胞质中的蛋白质。然而,利用 CMA 介导的蛋白降解来降解癌症治疗中的靶蛋白尚未得到广泛应用。在本研究中,我们开发了一种伴侣蛋白靶向嵌合体(CMATAC),以有效地、特异性地降解肿瘤细胞中的信号转导和转录激活因子 3(STAT3)。CMATAC 由 STAT3 和热休克同源 70kDa 蛋白(HSC70)靶向肽通过连接子连接而成。为了有效地将 CMATAC 递送到肿瘤细胞中,使用脂质纳米颗粒(LNPs)包封 CMATAC(nCMATAC)并修饰胰岛素样生长因子 2 受体(IGF2R)靶向肽(InCMATAC)以实现肿瘤靶向和精确递药。通过模拟禁食的饮食(FMD)激活肿瘤细胞中的 CMA 途径。此外,FMD 处理通过上调 IGF2R 的表达强烈增强了 InCMATAC 的细胞摄取和肿瘤积累。结果,InCMATAC 在 A549 和 HCC827 肿瘤细胞中有效地降解了 STAT3 蛋白,并抑制了体内肿瘤的生长。本研究表明,InCMATAC 可用于癌症治疗中的选择性蛋白降解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验